Summary of diseased recipient mice that received transplants of HSCs expressing oncogenic Kras
| Malignant lineage(s) . | No. mice . | Diagnosis . |
|---|---|---|
| Myeloid cells and T-cell linage | 1 | Severe JMML and T-cell lymphoblastic lymphoma |
| Myeloid cells alone | 2 | Severe JMML |
| T-cell lineage alone | 19 | 15 mice with T-cell lymphoblastic lymphoma; 4 mice with T-cell leukemia |
| Malignant lineage(s) . | No. mice . | Diagnosis . |
|---|---|---|
| Myeloid cells and T-cell linage | 1 | Severe JMML and T-cell lymphoblastic lymphoma |
| Myeloid cells alone | 2 | Severe JMML |
| T-cell lineage alone | 19 | 15 mice with T-cell lymphoblastic lymphoma; 4 mice with T-cell leukemia |
HSCs in which oncogenic Kras expression had been induced were purified as CD41−CD48−CD150+ cells. A total of 20 purified HSCs were transplanted into lethally irradiated mice together with 2.5 × 105 helper cells. A total of 22 of 36 mice developed hematopoietic malignancies in multiple lineages, as tabulated here.